Wegovy vs Ozempic: Same Molecule, Different Label — What Actually Differs
Wegovy and Ozempic are the same molecule (semaglutide) made by Novo Nordisk. Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg. Insurance, copay, and supply availability are usually the deciding factor.
If you have spent any time in GLP-1 forums, you have seen the question a hundred times: "Wegovy or Ozempic?" The answer is mostly anticlimactic — they are the same drug. The differences are bureaucratic, not pharmacological.
The molecule
Both are semaglutide, manufactured by Novo Nordisk. Semaglutide is a synthetic GLP-1 receptor agonist with a half-life of about a week, which is why both products are once-weekly injections.
When researchers run head-to-head trials at the same dose, the results are indistinguishable. Same appetite suppression. Same nausea profile. Same effect on blood sugar.
The differences in one table
| Wegovy | Ozempic | |
|---|---|---|
| Molecule | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA approval | Chronic weight management | Type 2 diabetes |
| Max dose | 2.4 mg/week | 2.0 mg/week |
| Doses | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | 0.25 → 0.5 → 1.0 → 2.0 mg |
| Insurance | Often covered for BMI ≥30 (or ≥27 with comorbidity) | Often covered for diabetes only |
Why the labels exist
In 2017, Ozempic was approved for type 2 diabetes. Doctors immediately noticed that diabetic patients lost dramatic amounts of weight on it, and started prescribing it off-label for obesity. Novo Nordisk saw the demand, ran a dedicated obesity trial (STEP), and got the FDA to approve a higher-dose version under the new brand name Wegovy in 2021.
Same drug, two labels — because U.S. insurance coverage attaches to the labeled indication, not the molecule.
Which one will your insurance cover?
This is usually the only practical question:
- If you are a diabetic, Ozempic is much more likely to be covered.
- If you are non-diabetic with a BMI ≥30 (or ≥27 with comorbidity like hypertension or sleep apnea), Wegovy is the labeled product and the one your insurer will look for.
- Many plans cover neither. PA (prior authorization) and step therapy are the rule, not the exception.
The clinical experience
The experience on Wegovy 2.4 mg is the same as on Ozempic if you stayed at 2.0 mg. The bump from 2.0 → 2.4 mg adds roughly 1–2 percentage points of additional weight loss in the published trials, with a corresponding bump in side effects. Most patients tolerate the 1.7 mg dose well; the move to 2.4 mg is the one that often re-introduces nausea.
Whatever brand — same protein floor
Whichever label is on your pen, the underlying problem is identical: the appetite suppression is so aggressive that hitting your protein floor by accident is impossible. Both Wegovy and Ozempic require a deliberate plan to:
- Eat 0.7–1.0 g/lb of goal-weight protein
- Resistance train 2–3 sessions per week
- Stay hydrated through the GI side effects
- Build maintenance habits before you stop
That plan is what determines whether you keep the result. The brand on the box does not.
Bottom line
Pick whichever your insurance covers and your pharmacy can actually dispense this month. The molecule is the same, the side-effect profile is the same, and the muscle-loss risk is the same. The discipline you bring to protein and lifting matters more than which brand of pen you got.